Aim: This study provides real-world insight into patient profile, clinical effectiveness and health-related quality of life among patients with advanced gastric/gastroesophageal junction (GEJ) adenocarcinoma treated with nivolumab. Materials & methods: Data were collected from medical records of patients with advanced GEJ adenocarcinoma treated with nivolumab in a UK Early Access to Medicines Scheme and from the patient-reported EuroQoL five dimensions questionnaire. Results: Evaluable patients (n = 113; median age 62 years) were predominantly male (76.1%), White (87.4%) and with GEJ adenocarcinoma (61.9%). Median follow-up was 2.8 months. The 6-month progression-free survival and overall survival were 31.6 and 56.7%, respectively. Mean EuroQoL five dimensions questionnaire index utility scores at baseline, 8, 16 and 24 weeks were 0.795, 0.831, 0.870 and 0.793, respectively. Conclusion: Progression-free survival was consistent with trial results and health-related quality of life remained stable over time.
Keywords: ATTRACTION-2; CheckMate-032; Early Access to Medicines Scheme; gastric/gastrointestinal adenocarcinoma; health-related quality of life; medical records; nivolumab; real-world.
Lay abstract This study looked at the characteristics and quality of life (QoL) of patients who were taking the drug, nivolumab, and how well it works for advanced gastric/gastroesophageal junction (GEJ) adenocarcinoma. GEJ adenocarcinoma is a rare type of cancer that starts in the GEJ, the area where the esophagus and stomach join. Information was collected from the medical records of patients who had advanced GEJ adenocarcinoma and were treated with nivolumab as part of a UK program that gives people access to new treatments that are not yet licensed. Patients also filled out a questionnaire called the EuroQoL five dimensions questionnaire that focuses on a patient’s quality of life (QoL). In total, 113 patients were a part of the study. The midpoint of all patients’ ages was 62 years and they were mostly males (76.1%), Whites (87.4%) and with GEJ adenocarcinoma (61.9%). The midpoint of follow-up time was 2.8 months. The percentages of patients meeting progression-free survival for 6 months, a period when a patient lives with GEJ adenocarcinoma but it does not get worse, and overall survival were 31.6 and 56.7%, respectively. Mean EuroQoL five dimensions questionnaire index scores (comprised between zero and one, the higher the better) at treatment start, 8, 16 and 24 weeks were 0.795, 0.831, 0.870 and 0.793, respectively. Progression-free survival was similar to clinical trial results and QoL was constant over time.